Publication Listing for the MeSH term bladder cancer. Found 17 abstracts
Majewski T, Yao H, Bondaruk J, Chung W, Lee S, Lee JG, Zhang S, Cogdell D, Yang G, Choi W, Dinney C, Grossman HB, Logothetis C, Scherer SE, Guo CC, Zhang L, Wei P, Weinstein JN, Issa JP, Baggerly K, McConkey DJ, Czerniak B. Whole-Organ Genomic Characterization of Mucosal Field Effects Initiating Bladder Carcinogenesis. Cell Rep. 2019 Feb 19;26(8):2241-2256e4. |
Martini A, Jia R, Ferket BS, Waingankar N, Plimack ER, Crabb SJ, Harshman LC, Yu EY, Powles T, Rosenberg JE, Pal SK, Vaishampayan UN, Necchi A, Wiklund NP, Mehrazin R, Mazumdar M, Sfakianos JP, Galsky MD. Tumor downstaging as an intermediate endpoint to assess the activity of neoadjuvant systemic therapy in patients with muscle-invasive bladder cancer. Cancer. 2019 May 31;125(18):3155-63. |
Abbosh PH, Plimack ER. Molecular and Clinical Insights into the Role and Significance of Mutated DNA Repair Genes in Bladder Cancer. Bladder cancer (Amsterdam, Netherlands). 2018 Jan 20;4(1):9-18. PMCID: PMC5798524 |
Agarwal N, Pal SK, Hahn AW, Nussenzveig RH, Pond GR, Gupta SV, Wang J, Bilen MA, Naik G, Ghatalia P, Hoimes CJ, Gopalakrishnan D, Barata PC, Drakaki A, Faltas BM, Kiedrowski LA, Lanman RB, Nagy RJ, Vogelzang NJ, Boucher KM, Vaishampayan UN, Sonpavde G, Grivas P. Characterization of metastatic urothelial carcinoma via comprehensive genomic profiling of circulating tumor DNA. Cancer. 2018 May 15;124(10):2115-24. |
Klaassen Z, Arora K, Goldberg H, Chandrasekar T, Wallis CJ, Sayyid RK, Fleshner NE, Finelli A, Kutikov A, Violette PD, Kulkarni GS. Extended Venous Thromboembolism Prophylaxis After Radical Cystectomy: A Call for Adherence to Current Guidelines. J Urol. 2017 Nov 04;. |
Ramos JD, Casey MF, Bamias A, De Giorgi U, Bellmunt J, Harshman LC, Ladoire S, Wong YN, Alva AS, Rosenberg JE, Galsky MD, Yu EY, Retrospective International Study of Cancers of the Urothelium I. The Khorana Score in Predicting Venous Thromboembolism for Patients With Metastatic Urothelial Carcinoma and Variant Histology Treated With Chemotherapy. Clin Appl Thromb Hemost. 2017 Oct;23(7):755-60. |
Ramos JD, Casey MF, Crabb SJ, Bamias A, Harshman LC, Wong YN, Bellmunt J, De Giorgi U, Ladoire S, Powles T, Pal SK, Niegisch G, Recine F, Alva A, Agarwal N, Necchi A, Vaishampayan UN, Rosenberg JE, Galsky MD, Yu EY, Risc Investigators. Venous thromboembolism in metastatic urothelial carcinoma or variant histologies: incidence, associative factors, and effect on survival. Cancer medicine. 2017 Jan;6(1):186-94. PMCID: PMC5269690 |
Tong C, Daskalakis N, Edwards DC, Cahn DB, Belkoff L, Geynisman DM. Malignant Infiltration of the Penis From Urothelial Carcinoma of the Bladder. Urology. 2017 Sep;107:23-5. PMCID: Review |
Uzzo RG, Horwitz EM, Plimack ER. Fox Chase Cancer Center's Genitourinary Division: a national resource for research, innovation and patient care. Future Oncol. 2016 Feb 17;12(7):887-91. |
Zibelman M, Plimack ER. Systemic therapy for bladder cancer finally comes into a new age. Future Oncol. 2016 Oct;12(19):2227-42. PMCID: PMC5066115 |
Corcoran AT, Handorf E, Canter D, Tomaszewski JJ, Bekelman JE, Kim SP, Uzzo RG, Kutikov A, Smaldone MC. Variation in performance of candidate surgical quality measures for muscle-invasive bladder cancer by hospital type. BJU international. 2015 Feb;115(2):230-7. |
Galsky MD, Pal SK, Chowdhury S, Harshman LC, Crabb SJ, Wong YN, Yu EY, Powles T, Moshier EL, Ladoire S, Hussain SA, Agarwal N, Vaishampayan UN, Recine F, Berthold D, Necchi A, Theodore C, Milowsky MI, Bellmunt J, Rosenberg JE, Retrospective International Study of Cancers of the Urothelial Tract I. Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle-invasive bladder cancer. Cancer. 2015 Aug;121(15):2586-93. |
Ibragimova I, Dulaimi E, Slifker MJ, Chen DY, Uzzo RG, Cairns P. A global profile of gene promoter methylation in treatment-naive urothelial cancer. Epigenetics. 2014 May;9(5):760-73. PMCID: Pmc4063835 |
Hoffman AM, Cairns P. Epigenetics of kidney cancer and bladder cancer. Epigenomics. 2011 Feb;3(1):19-34. PMCID: NIHMS362391 |
Makhlin I, Zhang J, Long CJ, Devarajan K, Zhou Y, Klein-Szanto AJ, Huang M, Chernoff J, Boorjian SA. The mTOR pathway affects proliferation and chemosensitivity of urothelial carcinoma cells and is upregulated in a subset of human bladder cancers. BJU international. 2011 Jul;108(2B):E84-E90. PMCID: PMC3116980 |
Chakravarti A, Winter K, Wu CL, Kaufman D, Hammond E, Parliament M, Tester W, Hagan M, Grignon D, Heney N, Pollack A, Sandler H, Shipley W. Expression of the epidermal growth factor receptor and Her-2 are predictors of favorable outcome and reduced complete response rates, respectively, in patients with muscle-invading bladder cancers treated by concurrent radiation and cisplatin-based chemotherapy: A report from the Radiation Therapy Oncology Group. International Journal of Radiation Oncology Biology Physics. 2005 Jan;62(2):309-17. |
Mason TJ, Walsh WP, Lee K, Vogler W. New opportunities for screening and early detection of bladder cancer. Journal of cellular biochemistry. 1992 Jan;50(SUPPL. 16 I):13-22. |
MeSH cloud from publications including the MeSH term bladder cancer
bladder cancer
radical cystectomy
urothelial carcinoma
cisplatin
venous thromboembolism
immunotherapy
pathology
Neoadjuvant Therapy
mortality
neoadjuvant chemotherapy
upper tract urothelial carcinoma
chemotherapy
Urinary Bladder Neoplasms
methylome
Deoxycytidine
therapeutic use
CPG ISLAND METHYLATION
administration & dosage
Multicenter Studies as Topic
urothelial cancer
metastatic urothelial carcinoma
Her-2
germline mutations
translational application
Khorana score
Epidermal growth factor receptors (EGFR)
leukocytosis
RCC
DNA METHYLATION
Pd-1
mouse model
MICROSATELLITE
screening
methylation
surgical volume
penile metastasis
DNA methylation
epidermal growth factor receptor 2
Muscle Neoplasms
plus cisplatin
chemoresponse
Fox Chase Cancer Center
kidney cancer
Disease control
therapeutic strategy
in-vitro
gemcitabine plus cisplatin
therapy
dna methylation
analogs & derivatives
Treatment Outcome
CELL CARCINOMA
circulating tumor DNA
extended prophylaxis
Pfizer and Bristol-Myers Squibb and has received institutionally Novartis
Combined Modality Therapy
Neoplasm Metastasis
doxorubicin
clinical trials
HUMAN COLON
manuscript
methods
Urothelial
disclosed No writing assistance was utilized in the production of this
quality measures
Radiotherapy
Male
clonal expansion
HYPERMETHYLATION
The authors have no other relevant affiliations or financial involvement with any
Tumors
penile carcinoma
cpg-island methylation
BLADDER-CANCER
early cancer
statistics & numerical data
Multivariate analysis
precision medicine
gene signature
Retrospective Studies
renal cell
Female
COLORECTAL-CANCER
institutionally directed clinical trial support from Horizon Pharma ER Plimack
organization or entity with a financial interest in or financial conflict with
the subject matter or materials discussed in the manuscript apart from those
clear-cell
Biological organs
Methotrexate
neoadjuvant
tumor-suppressor gene
Biochemistry & Molecular Biology
Proteins
expression
gene
DNA damage response
tumor suppressor gene
colorectal-cancer
carcinoma
transitional cell carcinoma
DNA copy alterations
muscle invasion
next-generation sequencing
e-cadherin
Antineoplastic Combined Chemotherapy Protocols
INSTABILITY
renal-cell carcinoma
biomarkers
checkpoint blockade
mTOR
CIMP
COMPREHENSIVE GENOMIC CHARACTERIZATION
Eli Lilly has served on advisory boards and as consultant for Genentech
aberrant promoter
clonal origins
Whole-organ map
hypermethylation
Vinblastine
epidermal growth factor receptor
growth-factor-beta
Epidermal growth factor receptor
Oncology
hematuria
repair
founder mutation
Adult
inhibition
early detection
AstraZeneca and Merck directed clinical trial support from Bristol-Myers Squibb
Immunotherapy
hospital type
vinblastine
rapamycin
Middle Aged
MUTATIONS
Chemotherapy
chemotherapy survival
80 and over Aged
Cisplatin
prostate cancer
Radiation Therapy Oncology Group (RTOG)
Transitional Cell Carcinoma
Ctla-4
genitourinary cancer
Immunostaining
field effect
promoter hypermethylation
Genetics & Heredity
TET2
mammalian target